Study · Randomized controlled trial · 2009

11 results

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.

Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, Düring M, Zdravkovic M, Strauss BJ, Garber AJ

Diabetes, obesity & metabolism1 Dec 2009Cited by 236 (Europe PMC)

PMID19930006DOI10.1111/j.1463-1326.2009.01158.xPepBankPUB-19930006

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, liraglutide 1.2 and 1.8 mg reduced fat percentage significantly more than glimepiride.
In plain wordsIn adults with type 2 diabetes, liraglutide reduced body fat percentage more than glimepiride did.
Peptide
Liraglutide
Outcome
DecreaseFat percentage (LEAD-2)
Study
n: not reported in source
Comparator
Glimepiride plus metformin
Outcome group
Body composition · Metabolic and weight
Studied dose
1.2 and 1.8 mg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
LEAD-2: fat percentage with liraglutide 1.2 and 1.8 mg/metformin was significantly reduced vs. glimepiride/metformin (p < 0.05)
2 context sentences(design, population, supporting numbers)
Summary · context
These were randomized, double-blind, parallel-group trials of 26 [Liraglutide Effect and Action in Diabetes-2 (LEAD-2)] and 52 weeks (LEAD-3).
Summary · context
Patients were randomized to liraglutide 1.8, 1.2 or 0.6 mg/day, placebo or glimepiride 4 mg/day, all combined with metformin 1.5-2 g/day in LEAD-2 and to liraglutide 1.8, 1.2 or glimepiride 8 mg/day in LEAD-3.
Report a problemFND-1993000601
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, the fat percentage reduction with liraglutide 1.2 and 1.8 mg was not significant versus placebo.
In plain wordsIn adults with type 2 diabetes, liraglutide did not reduce body fat percentage significantly more than placebo.
Peptide
Liraglutide
Outcome
No significant changeFat percentage (LEAD-2)
Study
n: not reported in source
Comparator
Placebo plus metformin
Outcome group
Body composition · Metabolic and weight
Studied dose
1.2 and 1.8 mg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
but not vs. placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
These were randomized, double-blind, parallel-group trials of 26 [Liraglutide Effect and Action in Diabetes-2 (LEAD-2)] and 52 weeks (LEAD-3).
Summary · context
Patients were randomized to liraglutide 1.8, 1.2 or 0.6 mg/day, placebo or glimepiride 4 mg/day, all combined with metformin 1.5-2 g/day in LEAD-2 and to liraglutide 1.8, 1.2 or glimepiride 8 mg/day in LEAD-3.
Report a problemFND-1993000602
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, visceral adipose tissue area fell from baseline in all liraglutide arms.
In plain wordsIn adults with type 2 diabetes, belly fat area fell from baseline with all liraglutide doses.
Peptide
Liraglutide
Outcome
DecreaseVisceral adipose tissue area change from baseline (LEAD-2)
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Studied dose
0.6, 1.2 and 1.8 mg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
Visceral and subcutaneous adipose tissue areas were reduced from baseline in all liraglutide/metformin arms.
2 context sentences(design, population, supporting numbers)
Summary · context
These were randomized, double-blind, parallel-group trials of 26 [Liraglutide Effect and Action in Diabetes-2 (LEAD-2)] and 52 weeks (LEAD-3).
Summary · context
Patients were randomized to liraglutide 1.8, 1.2 or 0.6 mg/day, placebo or glimepiride 4 mg/day, all combined with metformin 1.5-2 g/day in LEAD-2 and to liraglutide 1.8, 1.2 or glimepiride 8 mg/day in LEAD-3.
Report a problemFND-1993000603
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, subcutaneous adipose tissue area fell from baseline in all liraglutide arms.
In plain wordsIn adults with type 2 diabetes, fat area under the skin fell from baseline with all liraglutide doses.
Peptide
Liraglutide
Outcome
DecreaseSubcutaneous adipose tissue area change from baseline (LEAD-2)
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Studied dose
0.6, 1.2 and 1.8 mg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
Visceral and subcutaneous adipose tissue areas were reduced from baseline in all liraglutide/metformin arms.
2 context sentences(design, population, supporting numbers)
Summary · context
These were randomized, double-blind, parallel-group trials of 26 [Liraglutide Effect and Action in Diabetes-2 (LEAD-2)] and 52 weeks (LEAD-3).
Summary · context
Patients were randomized to liraglutide 1.8, 1.2 or 0.6 mg/day, placebo or glimepiride 4 mg/day, all combined with metformin 1.5-2 g/day in LEAD-2 and to liraglutide 1.8, 1.2 or glimepiride 8 mg/day in LEAD-3.
Report a problemFND-1993000604
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, the visceral adipose tissue area reduction with liraglutide 1.2 and 1.8 mg differed significantly from glimepiride.
In plain wordsIn adults with type 2 diabetes, liraglutide reduced belly fat area more than glimepiride did.
Peptide
Liraglutide
Outcome
DecreaseVisceral adipose tissue area versus glimepiride (LEAD-2)
Study
n: not reported in source
Comparator
Glimepiride plus metformin
Outcome group
Body composition · Metabolic and weight
Studied dose
1.2 and 1.8 mg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
Visceral and subcutaneous adipose tissue areas were reduced from baseline in all liraglutide/metformin arms. Except with liraglutide 0.6 mg/metformin, reductions were significantly different vs. changes seen with glimepiride (p < 0.05) but not with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
These were randomized, double-blind, parallel-group trials of 26 [Liraglutide Effect and Action in Diabetes-2 (LEAD-2)] and 52 weeks (LEAD-3).
Summary · context
Patients were randomized to liraglutide 1.8, 1.2 or 0.6 mg/day, placebo or glimepiride 4 mg/day, all combined with metformin 1.5-2 g/day in LEAD-2 and to liraglutide 1.8, 1.2 or glimepiride 8 mg/day in LEAD-3.
Report a problemFND-1993000605
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, the subcutaneous adipose tissue area reduction with liraglutide 1.2 and 1.8 mg differed significantly from glimepiride.
In plain wordsIn adults with type 2 diabetes, liraglutide reduced fat area under the skin more than glimepiride did.
Peptide
Liraglutide
Outcome
DecreaseSubcutaneous adipose tissue area versus glimepiride (LEAD-2)
Study
n: not reported in source
Comparator
Glimepiride plus metformin
Outcome group
Body composition · Metabolic and weight
Studied dose
1.2 and 1.8 mg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
Visceral and subcutaneous adipose tissue areas were reduced from baseline in all liraglutide/metformin arms. Except with liraglutide 0.6 mg/metformin, reductions were significantly different vs. changes seen with glimepiride (p < 0.05) but not with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
These were randomized, double-blind, parallel-group trials of 26 [Liraglutide Effect and Action in Diabetes-2 (LEAD-2)] and 52 weeks (LEAD-3).
Summary · context
Patients were randomized to liraglutide 1.8, 1.2 or 0.6 mg/day, placebo or glimepiride 4 mg/day, all combined with metformin 1.5-2 g/day in LEAD-2 and to liraglutide 1.8, 1.2 or glimepiride 8 mg/day in LEAD-3.
Report a problemFND-1993000606
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, the visceral adipose tissue area reduction with liraglutide did not differ significantly from placebo.
In plain wordsIn adults with type 2 diabetes, liraglutide did not reduce belly fat area significantly more than placebo.
Peptide
Liraglutide
Outcome
No significant changeVisceral adipose tissue area versus placebo (LEAD-2)
Study
n: not reported in source
Comparator
Placebo plus metformin
Outcome group
Body composition · Metabolic and weight
Studied dose
1.2 and 1.8 mg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
Visceral and subcutaneous adipose tissue areas were reduced from baseline in all liraglutide/metformin arms. Except with liraglutide 0.6 mg/metformin, reductions were significantly different vs. changes seen with glimepiride (p < 0.05) but not with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
These were randomized, double-blind, parallel-group trials of 26 [Liraglutide Effect and Action in Diabetes-2 (LEAD-2)] and 52 weeks (LEAD-3).
Summary · context
Patients were randomized to liraglutide 1.8, 1.2 or 0.6 mg/day, placebo or glimepiride 4 mg/day, all combined with metformin 1.5-2 g/day in LEAD-2 and to liraglutide 1.8, 1.2 or glimepiride 8 mg/day in LEAD-3.
Report a problemFND-1993000607
08HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, the subcutaneous adipose tissue area reduction with liraglutide did not differ significantly from placebo.
In plain wordsIn adults with type 2 diabetes, liraglutide did not reduce fat area under the skin significantly more than placebo.
Peptide
Liraglutide
Outcome
No significant changeSubcutaneous adipose tissue area versus placebo (LEAD-2)
Study
n: not reported in source
Comparator
Placebo plus metformin
Outcome group
Body composition · Metabolic and weight
Studied dose
1.2 and 1.8 mg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
Visceral and subcutaneous adipose tissue areas were reduced from baseline in all liraglutide/metformin arms. Except with liraglutide 0.6 mg/metformin, reductions were significantly different vs. changes seen with glimepiride (p < 0.05) but not with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
These were randomized, double-blind, parallel-group trials of 26 [Liraglutide Effect and Action in Diabetes-2 (LEAD-2)] and 52 weeks (LEAD-3).
Summary · context
Patients were randomized to liraglutide 1.8, 1.2 or 0.6 mg/day, placebo or glimepiride 4 mg/day, all combined with metformin 1.5-2 g/day in LEAD-2 and to liraglutide 1.8, 1.2 or glimepiride 8 mg/day in LEAD-3.
Report a problemFND-1993000608
09HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, the liver-to-spleen attenuation ratio increased with liraglutide 1.8 mg, possibly indicating reduced hepatic steatosis.
In plain wordsIn adults with type 2 diabetes, a scan measure linked to liver fat improved with liraglutide 1.8 mg, possibly meaning less fatty liver.
Peptide
Liraglutide
Outcome
IncreaseLiver-to-spleen attenuation ratio (LEAD-2)
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Studied dose
1.8 mg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
Liver-to-spleen attenuation ratio increased with liraglutide 1.8 mg/metformin possibly indicating reduced hepatic steatosis.
2 context sentences(design, population, supporting numbers)
Summary · context
These were randomized, double-blind, parallel-group trials of 26 [Liraglutide Effect and Action in Diabetes-2 (LEAD-2)] and 52 weeks (LEAD-3).
Summary · context
Patients were randomized to liraglutide 1.8, 1.2 or 0.6 mg/day, placebo or glimepiride 4 mg/day, all combined with metformin 1.5-2 g/day in LEAD-2 and to liraglutide 1.8, 1.2 or glimepiride 8 mg/day in LEAD-3.
Report a problemFND-1993000609
10HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on monotherapy, liraglutide reduced fat mass, which differed significantly from the increase with glimepiride.
In plain wordsIn adults with type 2 diabetes, liraglutide reduced body fat mass while glimepiride increased it.
Peptide
Liraglutide
Outcome
DecreaseFat mass (LEAD-3)
Study
n: not reported in source
Comparator
Glimepiride 8 mg/day
Outcome group
Body composition · Metabolic and weight
Studied dose
1.2 and 1.8 mg/day · 52 weeksAs given in this study (human).
Source sentences
Summary
LEAD-3: reductions in fat mass and fat percentage with liraglutide monotherapy were significantly different vs. increases with glimepiride (p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
These were randomized, double-blind, parallel-group trials of 26 [Liraglutide Effect and Action in Diabetes-2 (LEAD-2)] and 52 weeks (LEAD-3).
Summary · context
Patients were randomized to liraglutide 1.8, 1.2 or 0.6 mg/day, placebo or glimepiride 4 mg/day, all combined with metformin 1.5-2 g/day in LEAD-2 and to liraglutide 1.8, 1.2 or glimepiride 8 mg/day in LEAD-3.
Report a problemFND-1993000610
11HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on monotherapy, liraglutide reduced fat percentage, which differed significantly from the increase with glimepiride.
In plain wordsIn adults with type 2 diabetes, liraglutide reduced body fat percentage while glimepiride increased it.
Peptide
Liraglutide
Outcome
DecreaseFat percentage (LEAD-3)
Study
n: not reported in source
Comparator
Glimepiride 8 mg/day
Outcome group
Body composition · Metabolic and weight
Studied dose
1.2 and 1.8 mg/day · 52 weeksAs given in this study (human).
Source sentences
Summary
LEAD-3: reductions in fat mass and fat percentage with liraglutide monotherapy were significantly different vs. increases with glimepiride (p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
These were randomized, double-blind, parallel-group trials of 26 [Liraglutide Effect and Action in Diabetes-2 (LEAD-2)] and 52 weeks (LEAD-3).
Summary · context
Patients were randomized to liraglutide 1.8, 1.2 or 0.6 mg/day, placebo or glimepiride 4 mg/day, all combined with metformin 1.5-2 g/day in LEAD-2 and to liraglutide 1.8, 1.2 or glimepiride 8 mg/day in LEAD-3.
Report a problemFND-1993000611

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials3

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

3 trials · 2 completed · 1 stopped early · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT01761318

Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients

Leiden University Medical Centern = 50Nov 2013 to Mar 2016

Diabetes Mellitus Type 2 · Metabolic Syndrome · Cardiovascular Disease · Diastolic Dysfunction · Fatty Liver

Trial page ClinicalTrials.govUpdated 5 May 2016

CompletedPhase 3Results postedNCT00318461

To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together

Novo Nordisk A/Sn = 1,091May 2006 to Nov 2008

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 7 Mar 2017

TerminatedPhase 3Results postedNCT00294723

To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c

Novo Nordisk A/Sn = 746Feb 2006 to Nov 2008

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 7 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.